share_log

JD HEALTH(6618.HK):SOFTER REVENUE ON POST-COVID NORMALISATION;L-T VISION INTACT

中银国际 ·  Aug 22, 2023 15:46

JDH's 1H23 total revenue increased by 34% YoY to RMB27.1bn, -2% below consensus/ BOCIe. 12-month annual active customer (AAC) further rose to 168.6m as of end June. IFRS/ Non-IFRS NPM expanded to historical high at 5.8%/ 9.0% on GPM rebound, improved opex efficiency and interest income. We expect softer near- to mid-term revenue on post-Covid normalisation, weak macro on core direct sales businesses and their new initiatives' monetisations which are yet to bear fruits. But we believe their committed strategic priorities, investment plans and L-T vision remain intact. Maintain BUY but cut our DCF TP to HK$65.0.

Key Factors for Rating

Intact strategies despite N-T pressure on post-Covid normalisation. We expect softer near- to mid-term revenue mainly on swifter and larger-than- expected Post-covid normalisation and weak macro. However, we deem Co will remain dedicated on their L-T visions by consistently executing their operational strategies and investment plans. We see user growth, supply chain management and improved efficiency are their 3 most important priorities in the near- to mid-term. We believe Co. will continue to i) enrich products/ services offerings; ii) offer high quality products/ services with competitive prices and supportive policies; iii) accelerate omni-channel/ O2O initiatives; iv) conduct branding campaigns especially in low-tier cities and offline consumption scenarios; v) make effective channel investments; and vi) deepen partnerships for user growth and brand awareness. Furthermore, Co. will keep optimise organizational structure for improved efficiency. Thus, we cut our near- to mid-term 2023/24/25E total revenue by -12%/-19%/-21% to factor in more profound post-Covid normalisation by scaling back our ARPU forecasts but maintaining our AAC forecasts. We largely keep our 2023-25E GPM forecasts unchanged while raising our 2023-25E bottom line estimations mainly to reflect our latest opex and non-operational item estimations, especially on interest income.

1H23 results: Topline miss but beat margin. Total revenue of RMB27.1bn(up 34% YoY) was -2% below consensus/ BOCIe. Product and service revenues were RMB23.2bn and RMB3.9bn, up by 34% and 44% YoY respectively. 12- month AAC further increased to 168.6m as of end June. GPM rose 1.1ppts YoY to 22.9%, beating consensus mainly on structural product mix shift and improved supply chain efficiency. IFRS/ Non-IFRS NPM reach historical high at 5.8%/ 9.0% on GPM rebound, improved opex efficiency and interest income (vs. 1.1%/ 6.0% in 1H22).

Key Risks for Rating

Downside risks: i) regulations; ii) Covid-normalisation; iii) destructive investments; iv) less support from JD Group; and v) fierce competition.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment